Aug 13, 2025 • Motley Fool
SOMEWHAT-BULLISH
ProKidney Reports 78 Percent Gain in Q2
ProKidney ( NASDAQ:PROK ) , a biopharmaceutical company developing cell therapies for chronic kidney disease ( CKD ) , released its second quarter results on August 12, 2025. The main focus of the release was encouraging clinical updates for its lead product rilparencel, especially from the Phase ...
Jul 22, 2025 • Motley Fool
NEUTRAL
Meet the Biotech Stock That Rocketed 775% Higher
If you're looking for stocks that can make dramatic movements in a short time frame, the biotechnology space has what you crave. At the end of June, ProKidney ( NASDAQ: PROK ) stock was languishing at less than $1 per share. When the market closed on July 10, the stock was trading at $5.18 per ...
Jul 17, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
PROKIDNEY CP ( PROK ) Upgraded to Strong Buy: What Does It Mean for the Stock?
PROKIDNEY CP (PROK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Jul 17, 2025 • Zacks Commentary
NEUTRAL
Best Momentum Stocks to Buy for July 17th
PROK, ROKU and PHAR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 17, 2025.
Jul 17, 2025 • Motley Fool
SOMEWHAT-BULLISH
This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy?
Biotech stocks can be risky but exciting investments because they can soar quickly on positive news, such as a drug approval or simply the hope that they may soon have an approved treatment. They can drop just as quickly on negative news.
Jul 17, 2025 • Zacks Commentary
NEUTRAL
New Strong Buy Stocks for July 17th
PHAR, ROKU, PROK, MAG and KRP have been added to the Zacks Rank #1 (Strong Buy) List on July 17, 2025.